JATT III is a blank check company, or SPAC, formed to effect a merger, share exchange, asset acquisition, or business combination with one or more businesses. The company maintains no commercial operations or revenue and focuses its acquisition search on the healthcare and life sciences sectors, with a primary emphasis on biotechnology. Within biotechnology, JATT III targets early- and development-stage businesses applying data-driven technologies, such as machine learning, computational biology, and structure-based drug design, to improve drug discovery and development. JATT III's business model relies on raising capital via an IPO and holding those funds in trust while management evaluates potential acquisition targets. JATT III aims to leverage its management team's scientific, clinical, venture capital, and operational networks to identify targets, execute a transaction, and provide operational and capital markets support. If JATT III completes a business combination, the acquired company becomes a publicly traded entity; if a transaction is not completed within a set timeframe, JATT III must liquidate and return the trust capital to its public shareholders.